NCT04986436View on ClinicalTrials.gov

Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of HS-10360 in Healthy Subjects.

PHASE1UnknownINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

July 31, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Healthy
Interventions
DRUG

HS-10360

Single or multiple dose(s) of HS-10360

DRUG

Placebo

Single or multiple dose(s) of Placebo

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY